Three-Year Follow-up After Antiviral Treatment in New-Onset Type 1 Diabetes: Results From the Diabetes Virus Detection and Intervention Trial
Authors' conclusion
The decreased reduction in C-peptide levels after antiviral treatment is no longer present after 2 or 3 years. Further investigations are needed to explore options to use antiviral treatment in the prevention and treatment of T1D.
Study context
- Population
- Children and adolescents aged 6–15.9 years newly diagnosed with T1D75 attended 3-year follow-up
- Participants
- 96 children
- Comparison
- Antiviral treatment for 6 months vs placebo
- Primary endpoint
- Residual C-peptide secretion, AUC, assessed by 2-h mixed-meal tolerance test
Methodological detailsfollow-up of the Diabetes Virus Detection and Intervention trial, multicenter, placebo-controlled, randomized 1:1
- Follow-up of the Diabetes Virus Detection and Intervention trial
- Multicenter
- Placebo-controlled
- Randomized 1:1
Primary result
As reported in the abstract
C-peptide AUC · 3 years
Placebo
0.17
mean · SD 0.23
Pleconaril and ribavirin
0.25
mean · SD 0.34
Secondary outcomes
Mean
| Outcome | Pleconaril and ribavirin | Placebo |
|---|---|---|
| C-peptide AUC · 2 years | 0.34 (SD 0.37) | 0.27 (SD 0.33) |
C-peptide AUC · 2 years
- No statistically significant difference between the groups
Secondary end points (incl. insulin doses and HbA1c)
- Groups comparable with regard to secondary end points
Original publication
Three-Year Follow-up After Antiviral Treatment in New-Onset Type 1 Diabetes: Results From the Diabetes Virus Detection and Intervention Trial. Diabetes Care. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →